SVB Leerink

Moderna, Inc. (NASDAQ: MRNA) shares were solidly higher in premarket trading on Wednesday. What Happened: The upside in Moderna’s shares comes in reaction to a clinical readout announced late Tuesday, which showed that the Cambridge, Massachusetts-based company’s mRNA vaccine targeting...

Biogen, Inc. (NASDAQ: BIIB) and Eisai Co. Ltd. (OTC: ESALY) announced late Tuesday positive results from a late-stage study of their Alzheimer’s treatment candidate. What Happened:  Biogen and Eisai said the global Phase 3 confirmatory study, "Clarity...

Moderna, Inc. (NASDAQ: MRNA) reported better-than-expected fourth-quarter earnings Thursday and announced a slight upward revision to its vaccine sales forecast for 2022. The company also announced a $3-billion stock buyback. The stock rallied 15.1% in Thursday's trading session. Here's...

Pfizer, Inc. (NYSE: PFE) announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for use by the U.S. Food and Drug Administration. The Pfizer Analysts: SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer. BofA...

Pfizer, Inc. (NYSE: PFE) found huge success with its COVID-19 franchise that includes Comirnaty, the COVID-19 vaccine it co-developed with BioNTech SE (NASDAQ: BNTX), and its yet-to-be authorized oral COVID-19 pill Paxlovid. The Pfizer Analyst: SVB Leerink analyst Geoffrey Porges reiterated a...

InflaRx N.V. (NASDAQ: IFRX) shares are rallying hard Thursday. Here's why.  What Happened: German biopharma InflaRx, which focuses on developing therapies for autoimmune and inflammatory diseases, announced positive data Wednesday from the third cohort of patients in the Phase 2a study...

Sanofi SA (NASDAQ: SNY) shares traded higher by 0.4% on Monday after the company scored an analyst upgrade. The Analyst: SVB Leerink analyst Geoffrey Porges upgraded Sanofi from Market Perform to Outperform and raised his price target per U.S. ADR from $69.61 to $71.37. Related Link: Cigna Has...

While Humana Inc.’s (NYSE: HUM) stock already seems to price in the near-term concerns around rebounding medical costs and high COVID-19 costs, it offers an opportunity to gain exposure to “the post-COVID accelerating growth environment and associated 2022 inflection,” according...

FibroGen, Inc. (NASDAQ: FGEN) has a key catalyst Thursday when FDA's Cardiovascular and Renal Drugs Advisory Committee will issue its recommendation on the company's new drug application for roxadustat. The committee is scheduled to meet between 9:30 a.m. and 5:30 p.m. Roxadustat was ...

Biohaven Pharmaceutical Ltd. (NYSE: BHVN) released preliminary second-quarter revenue data for its drug Nurtec ODT on Wednesday. What Happened: Nurtec achieved preliminary net product revenue of approximately $93 million in the second quarter, according to the company. Since its launch in March...

Biogen Inc.'s (NASDAQ: BIIB) Alzheimer's treatment Aduhelm was approved by the FDA Monday, sending the company's shares up over 38%.  The Biogen Analysts: Morgan Stanley analyst Matthew Harrison maintained an Overweight rating on Biogen shares and increased the price target from...

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares came under pressure Monday after the Food and Drug Administration (FDA) rejected its regulatory application seeking label expansion for its dementia drug. The Acadia Analysts: Goldman Sachs analyst Salveen Richter downgraded Acadia shares...

908 Devices Inc (NASDAQ: MASS) is seen as a high-growth life science tools company that analysts at SVB Leerink expect to “outperform” despite conservative 2021 guidance given by its management due to the current visibility. The 908 Devices Analyst: SV Leerin analyst Puneet Souda has...

Novavax, Inc. (NASDAQ: NVAX) shares were roaring higher Friday after the company reported topline results from the late-stage trial of its coronavirus vaccine candidate in the U.K. The Novavax Analyst: H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating and $207 price target for...

Imara Inc (NASDAQ: IMRA) shares took a thrashing Wednesday following the release of mid-stage results of its IMR-687 in sickle cell disease. Underwhelming Data: IMR-687 failed to close part of the gap from the 1.7% absolute increase in fetal hemoglobin, or HbF, demonstrated at interim readout and...